Legal

Regulatory status by compound

For each compound this site covers: its status with FDA Philippines, the US FDA and the European Medicines Agency, each sourced and dated.

Short answer

As of 23 September 2026, none of the research peptides searched on the FDA Philippines verification portal is registered, and 6 were not searched. Semaglutide and tirzepatide are registered only as branded prescription medicines (Ozempic, Wegovy, Rybelsus and Mounjaro). A research-grade vial is not a registered medicine.

Status by compound

CompoundFDA PhilippinesUS FDAEMA
RetatrutideNo registered drug product found on the FDA verification portalInvestigationalNo record found
TirzepatideRegistered only as the branded prescription medicine Mounjaro (12 certificates)Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)Approved for type 2 diabetes mellitus and weight management (Mounjaro)
SemaglutideRegistered only as branded prescription medicines: Ozempic, Wegovy and Rybelsus (17 certificates of product registration)Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy)Approved for type 2 diabetes mellitus (Ozempic, Rybelsus), weight management (Wegovy) and non-cirrhotic MASH with F2 to F3 fibrosis (Kayshild)
BPC-157No registered drug product found on the FDA verification portalNo record foundNo record found
TB-500No registered drug product found on the FDA verification portalNo record foundNo record found
GHK-CuNot published: the FDA verification portal was not searched for this nameNo record foundNo record found
KPVNo registration found; FDA Advisory No. 2026-1013 warns against an unregistered KPV productNo record foundNo record found
NAD+No registration found; FDA Advisory No. 2025-0084 warns against an unregistered NAD productNo record foundNo record found
MOTS-cNot published: the FDA verification portal was not searched for this nameNo record foundNo record found
TesamorelinNo registered drug product found on the FDA verification portalApproved for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophyNot approved
CJC-1295Not published: the FDA verification portal was not searched for this nameNo record foundNo record found
IpamorelinNo registered drug product found on the FDA verification portalNo record foundNo record found
BremelanotideNot published: the FDA verification portal was not searched for this nameApproved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal womenNo record found
SemaxNot published: the FDA verification portal was not searched for this nameNo record foundNo record found
SelankNo registered drug product found on the FDA verification portalNo record foundNo record found
DSIPNot published: the FDA verification portal was not searched for this nameNo record foundNo record found

Sources

US FDA and EMA columns: the regulatory dataset in the Research Desk of Primara Labs, our partner and supplier, which records the Drugs@FDA and EMA source and check date for every cell. FDA Philippines column: this site's search of the FDA verification portal on 23 September 2026, and the registration numbers in the GLP-1 price tracker. Each compound's page repeats its row with the source notes.

The regulation hub

Sources checked 23 September 2026. Primary sources only: statutes, DOH and FDA Philippines issuances, the FDA verification portal and the Bureau of Customs. This is general information, not legal advice.

Updated